Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-GEA-977 first-line ABBV-400 dose optimization study in advanced gastroesophageal adenocarcinoma
MOH_2024-09-11_013634Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and adverse events and Antitumor activity. Started Sep 2024; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on MOH_2024-09-11_013634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-11_013634.